pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 27·1 min read
save

PhRMA pushes back as prescription drug spending continues to rise, according to STAT+ newsletter

Jul 27, 2026·read at STAT ↗Negative

STAT+ Health Care Inc. newsletter author Bob Herman reports on the growing concern that prescription drug spending is rising despite industry attempts to downplay it. The piece appears in the July 27, 2026 edition of the STAT+ weekly email.

The article highlights that PhRMA, the main pharmaceutical lobbying group, is urging the public and policymakers to ignore the clear increase in drug costs. It suggests the lobby’s messaging aims to deflect attention from the spending trend.

The newsletter excerpt notes the author’s focus on health-care finance, offers a way to contact him, and reminds readers that full access requires a subscription.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharma’s drug spending deflection”

read at STAT ↗
463 words · retrieved Jul 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISINGUltragenyx Pharmaceutical Inc.
topics
Duchenne Muscular DystrophyPeptide TherapeuticRare Disease

related stories

  • Aug 21‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing itFierce Biotech
  • Aug 14Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersBioPharma Dive
  • Aug 5STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safetySTAT
  • Jul 30STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and moreSTAT
  • Jul 30New funding, new jobs: 4 biotechs hiring after series B raisesBioSpace